Health-care companies rose as deal activity in the sector intensified.
Health-care companies rose as deal activity in the sector intensified.
GSK agreed to buy U.S. cancer-drug developer Nuvalent for $10.6 billion, the British pharmaceutical company's latest move to bolster its oncology business. That came on the heels of deals that saw Johnson & Johnson and Roche committing to spend billions of dollars on oncology acquisitions.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
June 09, 2026 17:29 ET (21:29 GMT)
GSK Boosts Cancer Portfolio, Acquires Nuvalent for $10.6 Billion
GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B
Gilead and Merck's latest trial success and flop
$10. 6 billion deal: GSK to buy US cancer specialist Nuvalent
Pharmalittle: We're reading about a $10.6 billion GSK deal, an AstraZeneca obesity pill, and more
GSK offers 40pc premium in US$10.6b bid for cancer drug developer Nuvalent
GSK in talks to buy cancer biotech Nuvalent for more than $9 billion
Small Biotech Catapults To Record High On $10.6 Billion Deal
GSK snaps up US cancer treatment firm Nuvalent in $10.6bn deal
UK pharma giant GSK to buy US-based cancer drugmaker Nuvalent for $10.6 billion
Health-care companies rose amid deal activity and demand for sectors less sensitive to inflation rates.
Health-care companies ticked down as deal activity offset fears about generic competition for one key category of drugs.
GSK Boosts Cancer Portfolio, Acquires Nuvalent for $10.6 Billion
GSK is buying Nuvalent, the maker of targeted cancer drugs, for $10.6 billion, a sizable addition to the latest run of biopharma…
AstraZeneca's GLP-1 pill, GSK's $10.6B cancer startup acquisition, and more biotech news from The Readout
British pharmaceutical giant GSK has announced a massive $10.6 billion deal to acquire Nuvalent. This Boston-based company…
